Breast cancer is a highly heterogeneous disease that ideally should be subcategorised according to genetic defects potentially reflecting prognostic and predictive information in order to assure optimal and individualised treatment for patients ([Sorlie *et al*, 2001](#bib19){ref-type="other"}). Adjuvant treatment with antioestrogens like tamoxifen is one of the most important treatment strategies used for breast cancer, saving many lives. The presence of oestrogen receptor-alpha (ER*α*) in tumour cells is essential for tamoxifen response, and together with the progesterone receptor it serves as a predictive factor for tamoxifen response in clinical practice ([EBCTC, 1998](#bib5){ref-type="other"}). Despite ER*α* expression some tumours do not respond or develop resistance to tamoxifen treatment, suggesting that the presence of ER*α* is not the only factor influencing tamoxifen response ([Ali and Coombes, 2002](#bib1){ref-type="other"}). Even though the rationale for treatment failure is not fully comprehended, co-factors to the ER*α* such as cyclin D1 might be implicated in the process, theoretically blocking tamoxifen response. Cyclin D1 is a cell cycle regulating protein with potential dual roles and in addition to activating cdk 4/6 and sequestering of cdk-inhibitors in the G1/S transition ([Zhou *et al*, 2001](#bib23){ref-type="other"}), the protein has cdk-independent functions and can act as a co-factor for ER*α* independent of ligand ([Neuman *et al*, 1997](#bib16){ref-type="other"}; [Zwijsen *et al*, 1997](#bib25){ref-type="other"}, [1998](#bib24){ref-type="other"}; [McMahon *et al*, 1999](#bib13){ref-type="other"}; [Lamb *et al*, 2000](#bib12){ref-type="other"}). It has further been shown that cyclin D1 overexpression can affect tamoxifen response in breast cancer cell lines ([Hui *et al*, 2002](#bib9){ref-type="other"}), but contradictory results have nevertheless been published regarding this potentially important feature for cyclin D1 ([Pacilio *et al*, 1998](#bib17){ref-type="other"}; [Bindels *et al*, 2002](#bib3){ref-type="other"}). No randomised clinical studies detailing cyclin D1 in ER*α* positive breast cancer with regards to tamoxifen response have been reported. Cyclin D1 knockout mice show a marked defect in breast epithelium development during pregnancy ([Sicinski *et al*, 1995](#bib18){ref-type="other"}) and tissue-specific overexpression of cyclin D1 leads to mammary hyperplasia and adenocarcinoma formation in mice models ([Wang *et al*, 1994](#bib22){ref-type="other"}), supporting the relevance for cyclin D1 in breast cancer development.

Besides a potential role for cyclin D1 in ER*α* response, cyclin D1 has also been linked to prognostic information in breast cancer. Cyclin D1 gene amplification in sporadic tumours as well as cyclin D1 RNA expression in ER*α* positive breast cancer has been correlated to poor prognosis ([Kenny *et al*, 1999](#bib11){ref-type="other"}; [Bieche *et al*, 2002](#bib2){ref-type="other"}; [Naidu *et al*, 2002](#bib15){ref-type="other"}). When studying protein levels, cyclin D1 overexpression has in contrast been associated with better outcome ([Gillett *et al*, 1996](#bib7){ref-type="other"}; [Hwang *et al*, 2003](#bib10){ref-type="other"}). Furthermore, cyclin D1 overexpression has been closely linked to ER*α* positivity ([Michalides *et al*, 1996](#bib14){ref-type="other"}; [van Diest *et al*, 1997](#bib21){ref-type="other"}). In order to better clarify the role of cyclin D1 in breast cancer we analysed a material of randomised postmenopausal breast cancer patients with long follow-up. Interestingly, cyclin D1 overexpression was associated with tamoxifen resistance despite the presence of ER*α*. Tumours overexpressing cyclin D1 were further associated with a slightly improved survival, and in summary we show that randomised treatment trials including an untreated control arm are necessary in order to differ predictive and prognostic information.

MATERIALS AND METHODS
=====================

Study design
------------

Between 1980 and 1987, 248 patients with primary breast cancer were enrolled in a clinical trial ([EBCTC, 1998](#bib5){ref-type="other"}) in the Northern Health Region of Sweden and randomised to adjuvant tamoxifen treatment (40 mg daily), *n*=123, for 2 years *vs* control, *n*=125. The aim of the study was to compare the effect of tamoxifen *vs* no treatment on overall survival. The inclusion criteria were postmenopausal patients \>55 years of age operated with modified radical mastectomy with curative intent. Postoperative radiotherapy was given to all patients with lymph node metastases. Hormone receptor status was not evaluated at time of diagnosis.

The median age at diagnosis was 66.5 years (55--75 years), the median tumour size was 25 mm (\>0--76 mm) and 159 node-negative patients and 86 node-positive patients were encountered. According to TNM-classification 65 patients with stage I disease, 175 patients with stage II and five patients with stage III disease, were included in survival analyses. Three patients could not be classified according to TNM.

The median follow-up time was 18 years (range 15--22 years) for surviving patients. At 10-years of follow-up 72 patients (58%) were alive in the control group and 76 (62%) in the tamoxifen group. In the control group 53 (42%) patients had died and in the tamoxifen group 47 (38%) patients had died. At the last follow-up 34% of the patients in the control group were alive, whereas 66% had died. In the tamoxifen group 34% were alive and 66% had died. All clinicopathological data together with clinical outcome are summarised according to treatment arm in [Table 1](#tbl1){ref-type="table"} Table 1Patient and tumour characteristics according to treatment**VariableTamoxifen treated patients (*n*=123)Control (*n*=125)***Age (years) median*66.2 (54.9--74.7)66.8 (55.2--74.9)   *Age (number)*   \>Median 66 years6065 \<Median 66 years6360   *Tumour size*   Median (mm)25.0 (3--55)24.5 (\>0--76) Size not known20   *Node status*   Node−8079 Node+4145 Not known21   *Stage*   I3035 II9085 III14 Not known21   *ERα fraction*   0--10%1929 10--90%1412 \>90%5355 Not known37 (30%)29 (23%)   *PR fraction*   0--10%4750 10--90%2022 \>90%1718 Not known39 (32%)35 (28%)   *Cyclin D1 fraction*   0--10%2121 10--90%5353 \>90%915 Not known40 (33%)36 (29%)   *Cyclin D1 intensity*   Negative01 Low45 Moderate5049 High2934 Not known40 (33%)36 (29%)   *10-year FU*   Alive7672 Dead4753   *Maximum FU*   Alive4242 Dead8183.

Tissue array and immunohistochemistry
-------------------------------------

Representative parts of the tumours were assembled in a tissue array using a manual tissue arrayer (Beecher Instruments Micro-array Technology, Woodland, MD, USA). For immunohistochemistry, paraffin sections of 4 *μ*m were de-paraffinised using xylen and rehydrated using descending concentrations of ethanol according to standard protocol. Antigen retrieval was achieved using 10 m[M]{.smallcaps} citrate buffer at pH 6.0 and microwave treatment, before incubations with antibodies to the ER*α* (M7047, 1 : 200, Dako A/S, Glostrup, Denmark) and cyclin D1 (M7155, 1 : 100, Dako). All stainings were performed in a Dako Techmate 500 (Dako). The specificity of the antibodies was confirmed by comparing the immunohistochemistry stainings of cell lines with Western blot reactivity (data not shown).

Analytical procedures
---------------------

The randomised study included both ER*α* positive and ER*α* negative breast cancers and we therefore initially delineated the fraction of ER*α* positive tumour cells in four groups (0, \<10, 10--90 and \>90%) for each patient. ER*α* was scored as positive if \>10% and the subfraction of \>90% was used for the analyses of a homogenous group of potentially highly tamoxifen responsive tumours. Cyclin D1 protein was monitored by two investigators scoring the tissue array samples according to intensity and fraction of the nuclear staining. Fraction was scored according to the same criteria as ER*α* and intensity was subjectively divided into four groups (negative, low, moderate, high), see [Table 1](#tbl1){ref-type="table"}. By using tissue array, staining variations between samples were minimised and positive samples could be used as supplements for internal controls. Concordance between the investigators was high and in the few cases of differing results, biopsies were re-evaluated and discussed to reach consensus. Relevant tissue array biopsies for ER*α*/cyclin D1 analyses were obtained for 167 tumours. In total, 56 biopsies contained insufficient tumour cells or did not sustain the staining process. A total of 44 tumours were ER*α* negative (0--10% positive fraction), 22 had 10--90% and 101 \>90% ER*α* positive cells ([Table 2](#tbl2){ref-type="table"} Table 2Cyclin D1 intensity and ER*α* fraction analysis **ER*α* fractionCyclin D1 intensity0--10%10--90%\>90%**Negative100Low315Moderate351350High5846Total (*n*=167)4422101). For the survival analysis both intensity and fraction of cyclin D1 were used ([Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"} Table 3Cyclin D1 fraction and ER*α* fraction analysis **ER*α* fractionCyclin D1 fraction0--10%10--90%\>90%**0--10%285710--90%161574\>90%0220Total (*n*=167)4422101).

Statistical analysis
--------------------

Kaplan--Meier\'s plot and log rank test were used when illustrating and calculating survival. All calculations were performed in SPSS version 11.0. An age-matched survival estimate for a control population in southern Sweden was obtained from the Cancer Registry in Lund, Sweden.

RESULTS AND DISCUSSION
======================

Of the 248 patients included in the randomised treatment trial, formalin-fixed material was available for 223 tumours and 106 of these patients were randomised to tamoxifen treatment and 117 to observation, as described in [Figure 1](#fig1){ref-type="fig"}Figure 1Illustration of the patient material, randomisation and distribution of the analyses results. ER*α* positivity is \>10% positive cells and the cyclin D1 results are based on intensity determinations. ^\*^No evaluable tumour cells in the array or the tumour did not sustain the staining process.. Of the 182 breast cancer samples that were possible to evaluate for ER*α* in the array, 74% were classified as positive, which is in agreement with other reports including postmenopausal patients ([Elwood and Godolphin, 1980](#bib6){ref-type="other"}). In total, 59% of the tumours showed \>90% ER*α* positive cells, which is slightly higher than expected compared to ELISA-based analyses ([Thorpe *et al*, 1993](#bib20){ref-type="other"}). A summary of the 172 samples that were possible to evaluate for cyclin D1, including intensity and fraction is presented in [Table 1](#tbl1){ref-type="table"}. The cyclin D1 and ER*α* analyses combined are presented in [Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}. The fraction of cyclin D1 positive tumour cells and the cyclin D1 intensity determinations correlated significantly (*P*\<0.0001, *r*=0.463) and were both used for the following survival analysis regarding tamoxifen response.

In the total cohort consisting of both ER*α* positive and negative tumours, tamoxifen treatment did not improve prognosis ([Figure 2A](#fig2){ref-type="fig"}Figure 2Kaplan--Meier plots for overall survival indicating randomisation to 2 years of tamoxifen treatment contra no treatment. (**A**) Overview of the entire cohort including both ER*α* positive and negative tumours. (**B**) The subgroup of 101 \>90% ER*α* positive breast cancer samples. (**C**, **D**) Overall survival for patients having tumours with \>90% ER*α* positivity in relation to cyclin D1 intensity (low/moderate or high expression). *P*-values are presented in a box with values at 10 years of follow-up (22 years of follow-up in parenthesis).). Patients with tumours lacking or expressing low ER*α* did, as expected, not show any significant difference in survival with tamoxifen, whereas there was a slightly improved survival for patients with tumours having \>10% ER*α* positive cells (*P*=0.4055 after 10 years of follow-up and *P*=0.6000 after 22 years). The 108 tumours with \>90% ER*α* positive cells showed nevertheless a more pronounced response to tamoxifen treatment as illustrated in [Figure 2B](#fig2){ref-type="fig"}, supporting that there was an increased effect of adjuvant tamoxifen treatment in ER*α* high tumours compared to tumours with moderately elevated ER*α* levels. In order to delineate the effect of cyclin D1 expression in relation to tamoxifen response, overall survival in patients with ER*α* positive tumours was stratified according to the fraction and intensity of cyclin D1 expression and potential differences between tamoxifen and no treatment were evaluated. The fraction of cyclin D1 positive cells did not seem to influence the effect of tamoxifen treatment and survival curves with an apparent tamoxifen benefit were comparable in the cyclin D1 fraction subgroups (data not shown). Similar results were obtained both for the entire ER*α* positive cohort and the subgroup of \>90% ER*α* positive tumours. In contrast, the cyclin D1 intensity analyses showed substantial differences in tamoxifen response. A total of 45% of the 101 ER*α* high tumours had high cyclin D1 intensity staining whereas 50% had moderate and 5% were cyclin D1 low. By this definition, around half of the ER*α* positive tumours overexpressed cyclin D1, which is in line with earlier reports ([Gillett *et al*, 1996](#bib7){ref-type="other"}; [Michalides *et al*, 1996](#bib14){ref-type="other"}). When analysing all ER*α* positive tumours separating moderate/low cyclin D1 from high cyclin D1 tumours, a clear distinction in tamoxifen response was observed. In the group with lower cyclin D1, there was a difference in survival between tamoxifen and no treatment in the entire ER*α* positive cohort (*P*=0.0509 at 10 years and *P*=0.0927 at 22 years). When analysing the 101 tumours with \>90% ER*α* positive cells this effect was even more distinct (*P*=0.0077 at 10 years, *P*=0.0211 at 22 years), as illustrated in [Figure 2C](#fig2){ref-type="fig"}. Surprisingly, the difference between tamoxifen and no treatment was completely eliminated for tumours with high cyclin D1 ([Figure 2D](#fig2){ref-type="fig"}). This suggests that overexpression of cyclin D1 was linked to tamoxifen treatment resistance despite high and homogenous ER*α* content.

Regarding survival and cyclin D1, the untreated control patients could be used to evaluate true prognostic information without the interference of treatment differences. The fraction of cyclin D1 positive cells was not associated with any prognostic data whereas there was a difference in survival for cyclin D1 groups based on intensity determination, as illustrated in [Figure 3](#fig3){ref-type="fig"}Figure 3Overall survival in relation to cyclin D1 intensity (low/moderate and high) in (**A**) all untreated patients, (**B**) untreated patients with \>90% ER*α* positive cells and (**C**) tamoxifen treated patients with \>90% ER*α* positive cells. *P*-values are presented in a box with values at 10 years of follow-up (22 years of follow-up in parenthesis).. For all untreated patients there was a mortality rate of 56 and 71% respectively for patients with cyclin D1 high contra cyclin D1 moderate/low tumours ([Figure 3A](#fig3){ref-type="fig"}). In the group of \>90% ER*α* positive tumours, there was an even more noticeable difference in survival for cyclin D1 high contra moderate/low tumours with mortality rates of 48 and 85% respectively ([Figure 3B](#fig3){ref-type="fig"}). This suggests that high levels of cyclin D1 were associated with an overall better prognosis than moderate or low cyclin D1 levels in untreated patients. Interestingly, the opposite was observed when analysing patients treated with tamoxifen only ([Figure 3C](#fig3){ref-type="fig"}) and especially when focusing on a rather short follow-up time. The apparent contrasting results for patients that received tamoxifen or not, clearly illustrates the importance of an untreated control patient group for prognostic studies and might further explain earlier divergent results reported concerning cyclin D1 and prognosis. The reason why the fraction of cyclin D1 and intensity of cyclin D1 produced different results regarding prognostic as well as predictive information is not clear. The fraction of cyclin D1 must be affected by the amount of cells in different cell cycle phases whereas the intensity potentially reflects the maximum protein expression independent of total proliferation. Cyclin D1 nuclear intensity has previously been linked to the degree of amplification of the cyclin D1 gene ([Michalides *et al*, 1996](#bib14){ref-type="other"}). It is well known that high cyclin D1 protein content in tumours is not always caused by gene amplification ([Buckley *et al*, 1993](#bib4){ref-type="other"}) and this might also influence the cyclin D1 fraction and intensity measurements in this material of breast cancer samples.

Our results using randomised untreated or tamoxifen treated patients with a long follow-up period indicate that cyclin D1 indeed affects tamoxifen response, which is in line with some of the published data using cell lines. In contrast to this study, [Han *et al* (2003](#bib8){ref-type="other"}) did not observe any difference in tamoxifen response in metastatic breast cancer when studying cyclin D1. This study was nevertheless rather limited and the patients were not randomised, which might explain the discrepancy. The most likely mechanistic explanation for the effect of cyclin D1 on tamoxifen response is either through a direct interaction between cyclin D1 and the ER*α*/SRC-1 complex or via its cell cycle regulatory function, as also supported by cell line studies ([Zwijsen *et al*, 1998](#bib24){ref-type="other"}). Cyclin D1 could potentially partially block the effect of tamoxifen on the ER*α* despite theoretically causing an oestrogen-independent low activation. An alternative model is that cyclin D1 could sequester cdk-inhibitors, thereby affecting the G1/S control and tamoxifen response.

It thus seems that a large fraction of patients who receive tamoxifen do not benefit from it and this could partially be mediated through cyclin D1. Despite the rather favourable prognosis for cyclin D1 high breast cancer patients, a substantial fraction indeed die in advance as illustrated in [Figure 4](#fig4){ref-type="fig"}Figure 4Overall survival in the patient group of \>90% ER*α* positive, cyclin D1 high breast cancers subdivided according to tamoxifen treatment or no treatment with indication of a calculated expected survival for an aged-matched non-breast cancer cohort. *P*-values are presented in a box with value at 10 years of follow-up (22 years of follow-up in parenthesis)., showing the overall survival for patients with cyclin D1 high tumours compared to the expected survival in an aged-matched population. The outcome for this large cohort of breast cancer patients could nevertheless theoretically be improved by specifically targeting cyclin D1 in conjunction with tamoxifen, representing a new treatment strategy for tamoxifen resistance in ER*α* positive cyclin D1 overexpressing breast cancer.
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